Who Owns Elekta Company?

Who owns Elekta today?

The story of Elekta began in 1972 and shifted dramatically with its 1994 Nasdaq Stockholm listing, enabling global expansion in radiotherapy and radiosurgery. The Leksell family legacy remains influential alongside major Nordic pension funds and international asset managers.

Elekta’s ownership mixes family influence with institutional investors; by 2025 the company had a market cap near 28.5 billion SEK, revenues around 19.5 billion SEK, and served over 6,000 hospitals worldwide.

Who Owns Elekta Company? Major shareholders include the Leksell family, large Nordic pension funds, and global asset managers influencing governance and R&D priorities. See product analysis: Elekta Porter's Five Forces Analysis

Founders and Early Ownership: Elekta originated from Lars Leksell’s clinical invention, the Gamma Knife, and Laurent Leksell’s commercialization efforts; initial equity was concentrated within the Leksell family, with limited allocations to key collaborators and early employees to align incentives.

Clinical origin

Lars Leksell contributed the Gamma Knife intellectual property developed at Karolinska Institute; clinical validation underpinned early credibility.

Entrepreneurial leadership

Laurent Leksell, with an MBA and PhD in Economics, led business operations and commercialization from 1972 onward.

Family-controlled equity

Initial ownership was tightly held by the Leksell family, preserving control during early product sales and growth.

Limited external dilution

Growth in the 1970s–1980s was primarily self-funded through Gamma Knife sales, avoiding major venture-capital dilution.

Early stakeholder alignment

Minor equity stakes were granted to clinical collaborators and early employees to align interests with company success.

Transition to public ownership

By the 1994 IPO, a dual-class share structure preserved family voting control while enabling public capital for strategic acquisitions.

Ownership and governance choices during the early decades shaped the Elekta ownership structure, maintaining clinical priorities while preparing for expansion; see Growth Strategy of Elekta for related context.

Key facts and figures

Founders and early ownership milestones that influenced Elekta’s corporate trajectory.

• 1972 — Company founded by Laurent Leksell to commercialize Lars Leksell’s Gamma Knife clinical innovation.
• Initial equity predominantly held by the Leksell family, with small allocations to collaborators and employees.
• 1970s–1980s growth funded mainly by product sales, limiting external investor dilution.
• 1994 IPO — Dual-class share structure implemented to retain family voting control while accessing public capital for acquisitions.

Key events reshaping Elekta ownership include the 1994 IPO, late-1990s and early-2000s acquisition-driven expansion (including Varian brachytherapy assets and IMPAC Medical Systems), multiple capital raises that attracted institutional investors, and the dual-class share structure that by 2025 concentrated control with the Leksell family despite dispersed capital ownership.

As of 2025, Elekta ownership shows Class A and Class B shares with voting asymmetry: the Leksell Familjestiftelse and Laurent Leksell hold Class A and direct stakes giving them approximately 30.4 percent of voting power while representing about 5.6 percent of capital; institutional investors collectively own roughly 65 percent of capital.

Major shareholder snapshot

Top institutional holders concentrate in Swedish pension and mutual funds, with growing international index ownership and a push toward governance transparency.

• Fjärde AP-fonden: ~8.2 percent of capital
• Swedbank Robur Funds: ~6.1 percent
• Nordea Investment Funds: ~4.5 percent
• Vanguard and BlackRock: ~3.2 percent and 2.8 percent respectively

Institutional dominance of Elekta stock ownership has driven the Elekta 2025 strategy toward recurring SaaS revenue and operational margin focus; for additional historical context see Brief History of Elekta

The Board of Directors of Elekta is dominated by the Leksell family through a dual-class share structure; Laurent Leksell chairs the Board and links founding vision to current management led by CEO Gustaf Salford, supported by independent directors with global healthcare and industrial expertise.

Voting power is concentrated via approximately 14,250,000 Class A shares and 368,773,205 Class B shares outstanding, creating a gap between economic interest and control that leaves the Leksell family with outsized influence over Board decisions and strategy.

Board control & voting dynamics

The dual-class structure secures strategic continuity but sustains debate on shareholder equality and accountability among international analysts.

• Dual-class share split: 14,250,000 Class A vs 368,773,205 Class B
• Chair Laurent Leksell ensures founder influence
• Independent directors protect B-shareholder interests
• Audit and Remuneration Committees tie pay to EBITA and CO2 targets

Stable dividends, a clear succession plan and active governance committees have minimized proxy contests; analysts continue to discuss one-share-one-vote reforms to address Elekta ownership and Elekta corporate structure concerns—see further detail on revenue and model in Revenue Streams & Business Model of Elekta.

Between 2022 and 2025 Elekta’s ownership profile shifted noticeably toward ESG-focused institutional investors, now representing over 40% of institutional shareholding; management also used buybacks and strategic alliances to reinforce capital efficiency and market positioning.

Consolidation in radiotherapy after Siemens Healthineers’ acquisition of Varian intensified speculation about Elekta’s independence while the Leksell family reiterated anchor ownership; analysts expect Board evolution by 2026 as younger Leksell members take more active governance roles amid AI-driven oncology developments.

ESG ownership rise

Institutional ESG participation surpassed 40%, reflecting Elekta’s role in expanding cancer care in underserved regions.

Share buyback

The 2024 repurchase of ~1.5% of B-shares was executed during volatile interest-rate conditions to return capital and signal confidence.

Competitive consolidation

Siemens Healthineers’ acquisition of Varian reshaped market dynamics and increased merger speculation around Elekta’s future.

Board succession

Analysts foresee Board changes by 2026 as the next Leksell generation assumes greater governance responsibilities amid AI and personalized medicine trends.

For background on Elekta’s guiding principles and how ownership aligns with corporate strategy see Mission, Vision & Core Values of Elekta.